Plain-English translation of NCT07079735 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After a heart transplant, your immune system is weakened by medications that prevent rejection, which puts you at risk for a serious virus called CMV. This trial is testing whether a newer preventive medication called works as well as the standard medication () to prevent this infection. The study wants to see if this medication is safe and effective for heart transplant patients, since it has been studied successfully in other types of transplant recipients.
While this medication has been proven safe and effective in kidney, lung, and stem cell transplant patients, there hasn't been enough research testing it in heart transplant patients specifically. Doctors currently use the standard medication for heart transplants, but the newer treatment might have fewer side effects. This trial will show whether it's safe to use this medication in your situation.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll be randomly assigned to receive either the newer preventive medication () or the standard medication () for 6 months to 1 year, depending on your risk level. If you receive , you'll also take an additional medication (acyclovir) to protect against another virus. Throughout the study, you'll have regular clinic visits and blood tests to monitor whether the medication is working and check for any side effects or signs of infection.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Columbia University
Collaborators
Cornell University
Enrollment target
~150 participants
Started
September 2025
Primary completion
January 2028
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Afsana Rahman, MD
Columbia University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.